Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study
2020
AbstractAims: This analysis evaluates the cost-effectiveness of first-line treatment with FOLFIRI + cetuximab vs FOLFIRI + bevacizumab (FOLFIRI-cet vs FOLFIRI-bev) for patients with RAS wild-type (...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
26
References
3
Citations
NaN
KQI